EDMONTON, ALBERTA--(CCNMatthews - March 1, 2005) - CV Technologies Inc. (CVT)
(TSX VENTURE:CVQ) today announces the beginning of a unique partnership project
to investigate the potential use of COLD-fX(R) as a "standard of care" for the
prevention of upper respiratory infections in Canadian nursing homes. The first
phase of the project is a pilot clinical study conducted among residents in up
to four Edmonton area continuing care facilities to examine tolerability.

Health Canada's weekly "Flu Watch" report indicates that so far this winter in
Canada there has been an average of 3 flu outbreaks a day in long term care
facilities and retirement lodges. Government statistics indicate that more than
700 people, mostly seniors, die from flu related complications in North America
each week during the winter months. Influenza is the fourth leading cause of
death in people over 65.

Capital Health and the University of Alberta have conducted two clinical trials
on COLD-fX(R) involving healthy adults in the Edmonton area for both prevention
and treatment of upper respiratory tract infections. Capital Health and CVT
have joined in a unique partnership with the Good Samaritan Society as part of
the new study which aims to enroll 200 residents over the next four months.
Recruitment has already begun.

Capital Health Medical Officer of Health, Dr. Gerry Predy, who is also Director
of the Northern Alberta Vaccine Trials and Evaluation Centre says, "Discovering
ways to reduce the impact of flu on seniors is an important public health
issue. While flu shots provide seniors with vital protection given their
vulnerability, we're always looking for ways to give them additional
protection. I'm hopeful that COLD-fX(R) might be beneficial in conjunction with
flu shots to help our seniors' population."

Dr. Elaine Stokes, a Geriatrician and Vice-President of Medical/Clinical
Services for the Good Samaritan Society echoes that view. She says, "Flu
outbreaks in continuing care facilities are constantly and diligently
monitored. When an infection is suspected, the centre is unable to admit new
residents transferring from a hospital, resulting in a prolonged stay in a much
more expensive hospital bed. This creates a backlog and generates significant
pressure on the entire health care system."

While influenza shots are very helpful in protecting seniors, the spectrum of
other protection is limited to only certain types of influenza strains,
providing no protection against other respiratory viruses. The current
pharmaceutical options are limited in supply, as well as in safety and
efficacy. In addition, the threat of a major influenza pandemic has escalated
with the continuing avian influenza outbreak in Asia.

CVT President, CEO & Chief Scientific Officer, Dr. Jacqueline Shan said,
previous studies involving more than 700 participants, including two
FDA-regulated studies in seniors, provided a good indication of the safety and
efficacy of COLD-fX(R) for upper respiratory infections. "We hope this first
phase of a study to explore COLD-fX(R) as a 'standard of care' in Canadian
nursing homes will provide us with important clinical data in the search for
ways to provide flu protection for this important 'at risk' segment of
society."

Each participant will be administered two capsules of COLD-fX(R) per day for a
period of 4 months. The safety of COLD-fX(R) use will be investigated and the
rate of influenza-like illness will be compared with other continuing care
facilities. The current study has received approval from both the Capital
Health/University of Alberta Research Ethics Board, as well as Health Canada's
Natural Health Products Directorate.

COLD-fX(R) is a proprietary natural health compound - a result of a decade of
research and development by a team of 25 scientists. In lab and clinical
studies - many published in medical journals - it has been shown to have an
excellent safety profile with no adverse side effects.

ABOUT CAPITAL HEALTH

Capital Health in Edmonton is Canada's largest academic health region,
providing complete health services to 1 million residents in the cities of
Edmonton, Fort Saskatchewan, Leduc, Spruce Grove and St. Albert, and the
counties of Leduc, Parkland, Strathcona and Sturgeon and part of Yellowhead
County. Capital Health serves a total of 1.6 million people across central and
northern Alberta, providing specialized services such as trauma and burn
treatment, organ transplants and high-risk obstetrics.

ABOUT GOOD SAMARITAN SOCIETY

The Good Samaritan Society (A Lutheran Social Service Organization) has over 55
years experience in providing continuing care, assisted living and other
specialized health care services and facilities in an innovative and care
environment. It is one of the largest voluntary health care provides in Canada.
The Society is a registered charity, government by a volunteer Board of
Directors, and has facilities in Edmonton, Stony Plain, Spruce Grove,
Evansburg, Lethbridge, Lacombe, Rocky Mountain House, Pincher Creek, Hinton,
Kelowna and Penticton.

ABOUT CV TECHNOLOGIES INC.

CV Technologies is a biotechnology company founded in 1992. It aims to become a
global leader in the development, distribution, marketing and selling of safe
and effective natural health products for disease prevention and health
maintenance. CVT's lead product is COLD-fX(R), strengthens the immune system
and is widely used as a leading anti-cold, anti-flu treatment.

This news release contains forward-looking statements that involve risks and
uncertainties, which may cause actual results to differ materially from the
statements made. For this purpose, any statements that are contained herein
that are not statements of historical fact may be deemed to be forward-looking
statements. Without limiting the foregoing, the words "believes",
"anticipates", "plans", "intends", "expects" and similar expressions are
intended to identify forward-looking statements. Such risks and uncertainties
include, but are not limited to, the need for capital, changing market
conditions, completion of clinical trials, patient enrolment rates, uncertainty
of pre-clinical, retrospective and early clinical trial results, the
establishment of manufacturing processes and new corporate alliances, the
timely development, regulatory approval and market acceptance of the Company's
products, and other risks detailed from time to time in the Company's filings
with Canadian securities authorities.

- 30 -